• Home
  • Search
  • Abstract 663: Diagnostic screen for lung cancer using high throughput metabolomics screen
  • Cite Icon1
  • https://doi.org/10.1158/1538-7445.am2019-663Copy DOI Icon

Abstract 663: Diagnostic screen for lung cancer using high throughput metabolomics screen

Show More
  • Abstract
  • Literature Map
  • Citations
  • Similar Papers
Abstract

Abstract Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States, cigarette smoking being leading cause of lung cancer. There are two main types of lung cancer small cell and non-small cell lung cancer (NSCLC). The most common type being NSCLC which accounts for 80-85% of all reported cases. The ability to rapidly detect / diagnose lung cancer at an early stage is critical to successful treatment selection and patient survival. The use of metabolic profiling in biomedical applications metabolic profiling is being deployed as a method for finding novel, mechanistic, biomarkers of disease with obvious potential for improving diagnosis, and patient stratification. Here we present a rapid, simple and reliable high throughput targeted LC/MS single platform, for the quantification/monitoring of small molecule metabolites, lipids and peptides. The methodology employs a single set of LC/MS conditions which facilitate TCA cycle, bile acids, biogenic amine, free fatty acids, acyl carnitines, lipids and 100 protein panel without need for user intervention. Plasma from pilot cohort of lung cancer a health control samples were evaluated using this new methodology. The methodology showed excellent reproducibility and accuracy. The peptide analysis showed that 10 peptides were shown to be markers of lung cancer, these are listed in Table 1. Acylcarnitines were quantified over a range of 5 - 625ng/mL data showed that the C14:2 tetradecadienoyl carnitine and C16:1 palmitoleoyl carnitine were elevated in lung cancer samples whereas the C8:1 octenoyl carnitine level was reduced in the lung cancer samples . Although deoxycholic acid and chendeoxycholic acid appeared to be reduced in the lung cancer samples this was determined to be not statistically relevant. A total of 29 amino acids were measured during the analysis. Using t-test with p-value FDR cutoff adjusted to 0.01 the data clearly showed that sarcosine was highly over-expressed in lung cancer samples. Table 1P02749Apolipoprotein HP19652Alpha-1-acid glycoprotein 2P68871Hemoglobin subunit betaP02671Fibrogen alpha chainP02656Apolipoprotein C-IIIP02750Leucine-rich alpha 2-glycoprotein (LRG)P00738HaptoglobinP02748Complement component C9P02763Alpha-1-acid glycoprotein 1P01011Alpha-1-antichymotrypsin Note: This abstract was not presented at the meeting. Citation Format: Robert S. Plumb, Lee Gethings, Andrew Peck. Diagnostic screen for lung cancer using high throughput metabolomics screen [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 663.

Similar Papers
  • Research Article
  • Citations1116

Cancer Progress and Priorities: Lung Cancer.

  • Oct 01, 2019
  • Cancer Epidemiology, Biomarkers & Prevention
  • Matthew B Schabath +1
  • Front Matter
  • Citations8

PACIFIC: Time for a surgical IIIA uprising

  • Jun 04, 2018
  • The Journal of Thoracic and Cardiovascular Surgery
  • Harvey I Pass
  • Research Article

Abstract 5268: Differential expression of insulin receptor isoforms in human lung cancer.

  • Apr 15, 2013
  • Cancer Research
  • Jiaqi Huang +11
  • Front Matter

Commentary: Postrecurrence survival in patients with lung cancer after curative surgery warrants systematic investigation to optimize management strategies

  • Apr 21, 2022
  • JTCVS open
  • Chi Sum Yuen +1
  • Addendum
  • Citations374

Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer: Suppression of Tumorigenic Property of Lung Cancer Cells and Their Sensitization to Doxorubicin-Induced Apoptosis by miR-1

  • Nov 01, 2008
  • Journal of Biological Chemistry
  • Mohd W Nasser +9
  • Research Article

Abstract 2616: The immunoproteasome subunit LMP2 as a novel therapeutic target for non-small cell lung cancer

  • Apr 15, 2011
  • Cancer Research
  • Marie Wehenkel +8
  • Supplementary Content
  • Citations6

Chemo-radiotherapy in lung cancer: state of the art with focus on the elderly population

  • Apr 01, 2006
  • Annals of Oncology
  • C Mantovani +5
  • Research Article
  • Citations2

Precise diagnosis of small cell and non-small cell lung cancer based on Raman spectroscopy.

  • Jul 01, 2025
  • Photodiagnosis and photodynamic therapy
  • Wendong Sun +6
  • Discussion
  • Citations21

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?

  • Apr 23, 2019
  • Journal of Thoracic Oncology
  • Jordi Remon +3
  • Discussion
  • Citations1

Reply: lung cancer diagnosis and staging centers.

  • Feb 15, 2013
  • American journal of respiratory and critical care medicine
  • Neal Navani +1
  • Research Article

Negative associations between macronutrient quality index and lung cancer incidence and mortality: results from the prostate, lung, colorectal, and ovarian cancer screening trial

  • Sep 22, 2025
  • Frontiers in Nutrition
  • Dazhan Feng +11
  • PDF
  • Research Article
  • Citations53

Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach

  • Apr 22, 2020
  • Frontiers in Oncology
  • Bihong T Chen +14
  • Research Article
  • Citations3

A systematic review of CAR T-cell therapy in lung cancer: Move forward or move on?

  • Jun 01, 2025
  • Journal of Clinical Oncology
  • Hong Ma +1
  • Research Article
  • Citations50

Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.

  • Nov 01, 1995
  • British Journal of Cancer
  • Wk Evans +3
  • Research Article

Present trends in the treatment of advanced non small-cell lung cancer.

  • Aug 01, 2003
  • Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • Tariq Parvez +3
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.